Pamela J Barry Duguid, MD | |
3201 W Gore Blvd, Suite 202, Lawton, OK 73505 | |
(580) 355-6731 | |
(580) 250-5806 |
Full Name | Pamela J Barry Duguid |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 3201 W Gore Blvd, Lawton, Oklahoma |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659366391 | NPI | - | NPPES |
100249780C | Medicaid | OK | |
100249780C | Other | OK | SOONERCARE |
5745331 | Other | OK | AETNA |
080108825 | Other | RAILROAD MEDICARE | |
125325000 | Other | OK | DOL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 18140 (Oklahoma) | Primary |
207Q00000X | Family Medicine | 18140 (Oklahoma) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Pamela J Barry Duguid, MD Po Box 785, Lawton, OK 73502 Ph: (580) 357-9984 | Pamela J Barry Duguid, MD 3201 W Gore Blvd, Suite 202, Lawton, OK 73505 Ph: (580) 355-6731 |
News Archive
Nearly 23 percent of American women of childbearing age met or exceeded the median blood levels for all three environmental chemical pollutants - lead, mercury, and PCBs - tracked in an analysis of data on thousands of women by Brown University researchers.
In the last decade, a new strain of MRSA has emerged that can spread beyond hospital walls, putting everyone at risk of contracting the dangerous bacterial infection. This particular strain of MRSA - known as USA300 - contains a chunk of genes not shared by any other strains, though it is unclear how this unique genetic material enables the bacteria to survive and persist in the community.
Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.
› Verified 5 days ago
Alexander F Degazon, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5602 Sw Lee Blvd, Southwest Medical Center, Lawton, OK 73505 Phone: 580-531-4700 |